IKNA - Ikena Oncology - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

40.57M

Cash

157.3M

Avg Qtr Burn

-18.2M

Short % of Float

5.07%

Insider Ownership

0.34%

Institutional Own.

73.75%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IK-175 (AHR Inhibitor) Details Solid tumor/s, Cancer, Bladder cancer, Urothelial carcinoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-930 (TEAD1) Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.